FDA– tag –
-
AI Accelerates Gene Editing Tool Development: Profluent Unveils OpenCRISPR-1, First AI-Designed Open-Source CRISPR, Heralding a New Era of Genomic Medicine
Facebook USA Overview Artificial intelligence is dramatically accelerating the development of gene editing tools. Profluent announced OpenCRISPR-1, the first AI-designed open-source gene editor, merging CRISPR technology with large langu... -
IPS HEART’s iPSC-Derived Cell Therapy ISX9-CPC Secures FDA Rare Pediatric Disease Designation, Advancing Clinical Trials for Cardiac & Rare Muscle Disorders
Facebook (IPS Heart) USA Overview IPS HEART announced that its iPSC-derived cell therapy, ISX9-CPC, received Rare Pediatric Disease Designation (RPDD) from the FDA. Targeting cardiac and rare muscle disorders, this designation positions ... -
Sickle Cell Gene Therapy Breakthrough: Broad Institute’s Base Editing Permanently Resolves Disease in 42 Patients; FDA Approval & Stanford Trial Expansion Underway
Facebook (Stanford Medicine) USA Overview In a significant advance for sickle cell disease (SCD) gene therapy, Broad Institute's base editing therapy has permanently resolved SCD in 42 patients, with 24-month follow-up data reported. Con... -
REPROCELL Pioneers Integrated iPSC Manufacturing Platform, Accelerating US Phase III Clinical Programs with AI-Enhanced Gene Editing and GMP Compliance
REPROCELL Japan Overview REPROCELL has launched a comprehensive iPSC manufacturing platform designed to accelerate the clinical development of iPSC-derived therapeutics, notably supporting a US Phase III program. The platform integrates ... -
SK Group Inks $795M Deal to Propel Biohaven’s Epilepsy Therapy Toward FDA Approval
Fierce Biotech USA Overview SK Group has signed a $795 million strategic agreement to accelerate Biohaven's epilepsy drug candidate towards U.S. FDA approval. This significant partnership highlights the importance of financing and develo... -
US FDA Launches Discussion on Generative AI Medical Device Regulatory Framework, Covering Risk Assessment and Post-Market Surveillance
Regulations.gov (via US FDA) USA Overview The US FDA released its first discussion paper on a federal regulatory framework for generative AI-enabled medical devices, soliciting public comments on approaches for risk assessment, pre-marke... -
Study Reveals Only 3 of 1,357 FDA-Cleared Medical AI Devices Verified for Real-World Patient Benefits
PLOS Digital Health USA Overview A new analysis published in PLOS Digital Health indicates that only 3 of 1,357 AI-powered medical devices cleared by the US FDA have undergone real-world testing to demonstrate actual patient health impro... -
US FDA Updates Approved Cell and Gene Therapy Products List, Featuring Iovance, Pfizer, Janssen, Ultragenyx Products
FDA USA Overview The US FDA has updated its website with the latest list of approved cell and gene therapy products. This list includes innovative products from leading biopharmaceutical companies such as Iovance Biotherapeutics, Pfizer,... -
US FDA Approves Only Hematopoietic Stem Cells and Limited Gene Therapies; Warns Against Unapproved Orthopedic and Cosmetic Stem Cell Treatments
Haute Living USA Overview As of 2026, the US FDA has approved only hematopoietic stem cells from umbilical cord blood for blood disorders and a few gene-based stem cell therapies for specific rare genetic diseases. The FDA is actively wa... -
Ultragenyx’s Gene Therapy GENGLYCOS™ for Glycogen Storage Disease Type 1a Receives US FDA Accelerated Approval
RegMedNet USA Overview The US FDA has granted accelerated approval to Ultragenyx Pharmaceuticals' gene therapy, GENGLYCOS™, for adult and pediatric patients aged 8 and older with Glycogen Storage Disease Type 1a (GSD1a). GSD1a is an ultr...
